Amonafide
Template:Short description Template:Cs1 config Template:Drugbox Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.[1][2]
It was being developed as an anti-cancer therapy by Antisoma.[3]
since 2008[update]Template:Dated maintenance category (articles)Script error: No such module "Check for unknown parameters"., it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.Script error: No such module "Unsubst".
See also
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov
Script error: No such module "Check for unknown parameters".
External links
- Amonafide entry in the public domain NCI Dictionary of Cancer Terms
- Clinical trials of amonafide at ClinicalTrials.gov
Script error: No such module "template wrapper".